Gilead Sciences (GILD) Tops Q2 EPS by 14c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.87, $0.14 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.07 billion.

GUIDANCE:

Gilead Sciences sees FY2021 EPS of $6.90-$7.25, versus the consensus of $7.07. Gilead Sciences sees FY2021 revenue of $24.4-25 billion, versus the consensus of $24.64 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Nucor projects Q3 2026 earnings above prior year, below estimates
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'